Systematic review with meta-analysis: Direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B

Alimentary Pharmacology and Therapeutics

Volumn 43, Issue 1, 2016, Pages 16-29

  Houot, M ^a   Ngo, Y ^a   Munteanu, M ^a   Marque, S ^b   Poynard, T ^c,d  

^a Biopredictive   (France)

^b Capionis   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ASPARTATE AMINOTRANSFERASE;

ASPARTATE AMINOTRANSFERASE PLATELET RATIO INDEX; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ELASTOGRAPHY; FIB4 INDEX; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST KIT; MEDICAL PARAMETERS; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; AREA UNDER THE CURVE; BAYES THEOREM; BIOPSY; BLOOD; DIAGNOSTIC IMAGING; PATHOLOGY;

AREA UNDER CURVE; ASPARTATE AMINOTRANSFERASES; BAYES THEOREM; BIOMARKERS; BIOPSY; ELASTICITY IMAGING TECHNIQUES; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS;

EID: 84983187899     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13446     Document Type: Review

References (47)

1. US Burden of Disease Collaborators. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA 2013; 310: 591-608.
2. Mohd-Hanafiah K, Groeger J, Flaxman AD, Wiersma ST,. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-42.
3. WHO Library Cataloguing-in-Publication Data. Guidelines for the screening, care and treatment of persons with hepatitis C infection. WHO April 2014. Available at: http://apps.who.int/iris/bitstream/10665/111747/1/9789241548755-eng.pdf?ua=1 (accessed 15 October 2015).
4. WHO Library Cataloguing-in-Publication Data. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. WHO March 2015. Available at: http://apps.who.int (accessed 15 October 2015).
5. Poynard T,. First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy. J Hepatol 2011; 54: 586-7.
6. Poynard T, Lebray P, Ingiliz P, et al,. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol 2010; 10: 40.
7. Poynard T, Aubert A, Bedossa P, et al,. A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology 1991; 100: 1397-402.
8. Gebo KA, Herlong HF, Torbenson MS, et al,. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology 2002; 36 (5 Suppl. 1): S161-72.
9. Chou R, Wasson N,. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med 2013; 158: 807-20.
10. Tsochatzis EA, Crossan C, Longworth L, et al,. Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C. Hepatology 2014; 60: 832-43.
11. Poynard T, Ngo Y, Munteanu M, et al,. Noninvasive markers of hepatic fibrosis in chronic hepatitis B. Curr Hepat Rep 2011; 10: 87-97.
12. Salkic NN, Jovanovic P, Hauser G, Brcic M,. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis. Am J Gastroenterol 2014; 109: 796-809.
13. Xu XY, Kong H, Song RX, et al,. The effectiveness of noninvasive biomarkers to predict hepatitis B-related significant fibrosis and cirrhosis: a systematic review and meta-analysis of diagnostic test accuracy. PLoS ONE 2014; 9: e100182.
14. Miller MH, Ferguson MA, Dillon JF,. Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease. Liver Int 2011; 31: 461-73.
15. Poynard T, Lassailly G, Diaz E, et al,. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. PLoS ONE 2012; 7: e30325.
16. Parkes J, Guha IN, Harris S, et al,. Systematic review of the diagnostic performance of serum markers of liver fibrosis in alcoholic liver disease. Comp Hepatol 2012; 11: 5.
17. Poynard T, Morra R, Ingiliz P, et al,. Biomarkers of liver fibrosis. Adv Clin Chem 2008; 46: 131-60.
18. Poynard T, de Ledinghen V, Zarski JP, et al,. FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate. Clin Res Hepatol Gastroenterol 2011; 35: 720-30.
19. Schuetz GM, Schlattmann P, Dewey M,. Use of 3x2 tables with an intention to diagnose approach to assess clinical performance of diagnostic tests: meta-analytical evaluation of coronary CT angiography studies. BMJ 2012; 345: e6717.
20. Woo G, Tomlinson G, Nishikawa Y, et al,. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010; 139: 1218-29.
21. Poynard T, Ngo Y, Perazzo H, et al,. Prognostic value of liver fibrosis biomarkers: a meta-analysis. Gastroenterol Hepatol (N Y) 2011; 7: 445-54.
22. Goodman SN,. Toward evidence-based medical statistics. 2: the Bayes factor. Ann Intern Med 1999; 130: 1005-13.
23. Sterne JA, Davey Smith G,. Sifting the evidence-what's wrong with significance tests? BMJ 2001; 322: 226-31.
24. AASLD guidelines. Available at: http://www.hcvguidelines.org/full-report/hcv-testing-and-linkage-care
25. EASL-ALEH Clinical Practice Guidelines. Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63: 237-64.
26. Imbert-Bismut F, Ratziu V, Pieroni L, et al,. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-75.
27. Wai CT, Greenson JK, Fontana RJ, et al,. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
28. Sterling RK, Lissen E, Clumeck N, et al,. APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-25.
29. Castéra L, Vergniol J, Foucher J, et al,. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-50.
30. Hartung J, Knapp G, Sinha BK,. Statistical Meta-analysis with Applications. NewYork: John Wiley & Sons, 2008. ISBN 978-0-470-29089-7.
31. Perazzo H, Pais R, Munteanu M, et al,. Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?" Clin Res Hepatol Gastroenterol 2014; 4: 432-9. pii: S22107401(14)00101-6.
32. Poynard T, Halfon P, Castera L, et al,. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem 2007; 53: 1615-22.
33. Lambert J, Halfon P, Penaranda G, et al,. How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited. Clin Chem 2008; 54: 1372-8.
34. Poynard T, Vergniol J, Ngo Y, et al,. Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®). J Hepatol 2014; 60: 706-14.
35. Poynard T, Vergniol J, Ngo Y, et al,. Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest) and elastography (FibroScan). J Hepatol 2014; 61: 994-1003.
36. Castera L,. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 2012; 142: 1293-302.
37. Poynard T, de Ledinghen V, Zarski JP, et al,. Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard. J Hepatol 2012; 56: 541-8.
38. Munteanu M, Ratziu V, Poynard T,. FibroStic: a large confirmatory study for non-invasive biomarkers accuracy, if correctly interpreted. J Hepatol 2011; 55: 233; author reply 234-5.
39. Tapper EB, Castera L, Afdhal NH,. FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice. Clin Gastroenterol Hepatol 2015; 13: 27-36.
40. Nascimbeni F, Lebray P, Fedchuk L, et al,. Significant variations in elastometry measurements made within short-term in patients with chronic liver diseases. Clin Gastroenterol Hepatol 2015; 13: 763-71.
41. Poynard T, Munteanu M, Deckmyn O, et al,. Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age. BMC Gastroenterol 2011; 11: 39.
42. Chao DT, Lim JK, Ayoub WS, Nguyen LH, Nguyen MH,. Systematic review with meta-analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase ≤ 40 IU/L and significant hepatic fibrosis. Aliment Pharmacol Ther 2014; 39: 349-58.
43. Poynard T, Munteanu M, Luckina E, et al,. Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard. J Hepatol 2013; 58: 928-35.
44. Pavlov CS, Casazza G, Nikolova D, et al,. Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. Cochrane Database Syst Rev 2015; 1: CD010542.
45. Bedossa P, Dargère D, Paradis V,. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57.
46. Mehta SH, Lau B, Afdhal NH, Thomas DL,. Exceeding the limits of liver histology markers. J Hepatol 2009; 50: 36-41.
47. Boursier J, de Ledinghen V, Poynard T, et al,. An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards. J Hepatol 2015; 62: 807-15.